Mimrylo earns FDA approval for Polycythemia Vera

Health

Mimrylo earns FDA approval for Polycythemia Vera

7 sourcesUpdated Aug 29, 2026

The FDA has approved Mimrylo (rusfertide) from Takeda as a first-in-class hepcidin mimetic for adults with polycythemia vera, a condition causing excessive red blood cell production. By limiting iron availability, Mimrylo reduces red blood cell formation and keeps hematocrit under the safe 45% threshold, addressing a key limitation of current therapies. The approval was based on the Phase 3 VERIFY trial, which showed a majority of patients achieved clinical response and experienced reduced need for phlebotomy and improved fatigue, with acceptable tolerability primarily limited to injection-site reactions and anemia. Mimrylo provides a new option beyond phlebotomy, hydroxyurea, interferons, and Jakafi for patients whose PV is not well controlled, potentially lowering the treatment burden for many. Takeda and its collaborators anticipate global regulatory expansion and note that the approval does not alter the company's fiscal guidance, while investor timelines and stock activity reflect the regulatory milestone. PV affects about 90,000 people in the U.S., and a large share remain uncontrolled on existing therapies, highlighting Mimrylo’s potential to reshape PV management.

In this story:

More on this story

Back to News

Photo: Towfiqu barbhuiya / Wikimedia Commons (Pexels)

Health

FDA Approves Rasonque for Metastatic PDAC; Price Concerns

The FDA approved Revolution Medicines' pancreatic cancer drug daraxonrasib, sold as Rasonque, the first therapy to target a genetic driver of the disease. In a trial of advanced/metastatic pancreatic cancer, median overall survival reached 13.2 months versus 6.7 with chemotherapy, signaling a potentially transformative option for patients who have received prior therapy.

169 sources

Photo: Fair Expert / Wikimedia Commons (CC BY-SA 4.0)

Health

FDA Authorizes Juul2 E-Cigarette

The FDA has authorized Juul Labs’ Juul2 e-cigarette system, including a device and 18 mg/mL tobacco- and menthol-flavored pods, and noted that a significant share of adult smokers switched from cigarettes to these products, with higher switching rates for menthol. Regulators emphasized that complete switching offers greater health benefits than dual use and that the agency approved these products because their population health benefits outweigh the risks, bringing the total FDA-authorized Juul items to 48 while signaling ongoing market expansion and future adult-focused flavor and strength applications.

00%

Other

6

Total sources7

Last updatedAug 29, 2026

Does this breakdown look right?

How it spread

Broke markets.businessinsider.com · Aug 28, 11:00 PMCenter +3h7 sources +7h on

Claim check

What each side asserts, disputes — or leaves out entirely.

Analyzing the coverage…

Where do you land?

Whose framing of this story rings truest to you?

Coverage

FiercePharmaCenterTakeda bolsters blood cancer portfolio with FDA nod for Mimrylo in polycythemia vera

londoninsider.co.ukOtherFDA Approves Takeda's (TAK) Mimrylo As First Hepcidin-Mimicking Treatment For Rare Blood Cancer

simplywall.stOtherProtagonist Therapeutics (PTGX) As MIMRYLO Approval Reshapes The Valuation Debate

Comments

Ask this story anything:

Free account · your comment posts right after signup

5 sources

Photo: Arne Müseler / Wikimedia Commons (CC BY-SA 3.0 de)

Health

FDA Approves Updated COVID-19 Vaccines Nationwide

The FDA has approved the updated Comirnaty XFG COVID-19 vaccine and related XFG-adapted formulations for fall 2026-2027, with immediate shipping to pharmacies, hospitals, and clinics for adults 65+ and younger individuals with underlying conditions at high risk. The approval, based on a broad body of clinical and real-world data, aligns with guidance to target current circulating variants and will extend access to the new vaccine across the United States.

12 sources